Product
DNL593
1 clinical trial
1 indication
Indication
Frontotemporal DementiaClinical trial
A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label ExtensionStatus: Active (not recruiting), Estimated PCD: 2025-11-01